Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sudden cardiac death among persons with diabetes aged 1-49 years: a 10-year nationwide study of 14 294 deaths in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sudden death in heart failure: do we understand what we observe?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Defibrillators for prevention from sudden cardiac death: is it that easy?-Authors' reply

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Markus Zabel
  • Rik Willems
  • Andrzej Lubinski
  • Axel Bauer
  • Josep Brugada
  • David Conen
  • Panagiota Flevari
  • Gerd Hasenfuß
  • Martin Svetlosak
  • Heikki V Huikuri
  • Marek Malik
  • Nikola Pavlović
  • Georg Schmidt
  • Rajevaa Sritharan
  • Simon Schlögl
  • Janko Szavits-Nossan
  • Vassil Traykov
  • Anton E Tuinenburg
  • Stefan N Willich
  • Markus Harden
  • Tim Friede
  • Jesper Hastrup Svendsen
  • Christian Sticherling
  • Béla Merkely
  • EU-CERT-ICD Study Investigators
Vis graf over relationer

AIMS : The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy.

METHODS AND RESULTS : We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537-0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class <III, and chronic obstructive pulmonary disease. Adjusted mortality associated with ICD vs. control was 27% lower (HR 0.731, 95% CI 0.569-0.938, P = 0.0140). Subgroup analyses indicated no ICD benefit in diabetics (adjusted HR = 0.945, P = 0.7797, P for interaction = 0.0887) or those aged ≥75 years (adjusted HR 1.063, P = 0.8206, P for interaction = 0.0902).

CONCLUSION : In contemporary ICM/DCM patients (LVEF ≤35%, narrow QRS), primary prophylactic ICD treatment was associated with a 27% lower mortality after adjustment. There appear to be patients with less survival advantage, such as older patients or diabetics.

TidsskriftEuropean Heart Journal
Udgave nummer36
Sider (fra-til)3437-3447
Antal sider11
StatusUdgivet - 21 sep. 2020

Bibliografisk note

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

ID: 60076231